- Eledon Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q1 2023 Eledon Pharmaceuticals Inc Earnings Call TranscriptMay 11, 2023€2.52 (-4.55%)Earnings
- Q4 2022 Eledon Pharmaceuticals Inc Earnings Call TranscriptMar 30, 2023€2.18 (+4.81%)Earnings
- Eledon Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 15, 2023
- Q3 2022 Eledon Pharmaceuticals Inc Earnings Call TranscriptNov 14, 2022€2.58 (+8.40%)Earnings
- Eledon Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference TranscriptSep 29, 2022
- Eledon Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Eledon Pharmaceuticals Inc at Gilmartin Group Inaugural Emerging Growth Company Showcase (Virtual) TranscriptAug 31, 2022
- Q2 2022 Eledon Pharmaceuticals Inc Earnings Call TranscriptAug 11, 2022€3.28 (+1.86%)Earnings
- Eledon Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Q1 2022 Eledon Pharmaceuticals Inc Earnings Call TranscriptMay 12, 2022€2.44 (+0.83%)Earnings
- Eledon Pharmaceuticals Inc at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 21, 2022
- Q4 2021 Eledon Pharmaceuticals Inc Earnings Call TranscriptMar 24, 2022€3.38 (+3.68%)Earnings
- Q3 2021 Eledon Pharmaceuticals Inc Earnings Call TranscriptNov 11, 2021€4.22 (-1.40%)Earnings
- Q2 2021 Eledon Pharmaceuticals Inc Earnings Call TranscriptAug 12, 2021€5.5 (+2.80%)Earnings
- Q1 2021 Eledon Pharmaceuticals Inc Earnings Call TranscriptMay 13, 2021€7.6 (-2.56%)Earnings
- Eledon Pharmaceuticals Inc at NobleCon Investor Conference (Virtual) TranscriptJan 20, 2021
Eledon Pharmaceuticals Inc at Gilmartin Group Inaugural Emerging Growth Company Showcase (Virtual) Transcript
Good afternoon, everyone. And thank you for joining us today for Gilmartin Group's Inaugural Emerging Growth Company Showcase.
My name is Stephen Jasper. I'm a member of the biotech team here at Gilmartin, and I'm really excited to welcome Eledon Pharmaceuticals. Joining me today are DA Gros, CEO; and Steve Perrin, President and Chief Scientific Officer.
Eledon is using its expertise in targeting the CD40 ligand pathway to develop potential treatments for people requiring an organ- or cell-based transplant and for people with autoimmune and neurodegenerative disease. The company's lead compound, tegoprubart, is being evaluated in four distinct indications: kidney transplantation, islet cell transplantation, ALS, and IgA nephropathy, or IgAN. And we look forward to discussing each program in a little more detail today.
As a reminder, if you're interested in asking a question today, please be sure to use the Ask a Question tab on the right hand of the webcast. And you can submit a question at any point during today's discussion.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)